Trial Profile

A Phase IIa/b Double-Blind, Randomised, Placebo-Controlled, Linear Trend Design Dose-Ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Dec 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (11 Dec 2006)
08 Feb 2010 Endpoint methodology added.
31 Jul 2008 Results were presented at the 12th International Conference on Alzheimer's Disease and Related Disorders.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com